Extra-corporeal membrane oxygenation temporary support for early graft failure after cardiac transplantation

• Published in: European journal of cardio-thoracic surgery Vol. 37; no. 2; pp. 343 - 349
• Main Authors: D’Alessandro, Cosimo, Aubert, Stéphane, Golmard, Jean Louis, Praschker, Beltran Levy, Luyt, Charles Edouard, Pavie, Alain, Gandjbakhch, Iradj, Leprince, Pascal
• Format: Journal Article
• Language: English
• Published: Germany Elsevier Science B.V 01.02.2010
• Subjects: Adolescent; Adult; Aged; Cardiac graft failure; Cardiotonic Agents - administration & dosage; Child; Drug Administration Schedule; ECMO; Extracorporeal Membrane Oxygenation - methods; Female; Graft Rejection - therapy; Heart Transplantation; Humans; Male; Mechanical circulatory support; Middle Aged; Organ Preservation - methods; Postoperative Care - methods; Survival Analysis; Tissue Donors; Treatment Outcome; Young Adult; ECMO; Cardiac graft failure; Mechanical circulatory support
• ISSN: 1010-7940; 1873-734X
• DOI: 10.1016/j.ejcts.2009.05.034

Objective: Early graft failure (EGF) is a major risk for death after heart transplantation. We studied the impact of an extra-corporeal membrane oxygenation (ECMO) temporary support on the operative mortality and the mean-term survival after EGF. Materials and methods: Between January 2000 and December 2006, 394 patients underwent orthotopic heart transplantation at our institution. EGF was observed in 90 (23%) patients. Fifty-four patients (14%) were treated with ECMO support, eight (2%) with other assisting devices, and 28 (7%) received maximal inotropic drug support only. Results: The overall mortality was 21% (83 patients). EGF was a major risk for death: 13% (35 patients) without EGF versus 58% (49 patients) with EGF, p ≪ 0001. Among patients supported with ECMO, 36 (67%) were weaned from the assisting device and 27 (50%) were discharged from the hospital. Overall survival was 73% at 1 year and 66% at 5 years. Absence of EGF improved long-term survival: 78% at 1 year and 70% at 5 years without EGF versus 37% at 1 year and 35% at 5 years with EGF. Patients treated with ECMO have the same 1-year conditional survival as patients not having suffered EGF: 94% at 3 years. Conclusions: ECMO support is a reliable therapeutic option in severe EGF after cardiac transplantation; furthermore, patients treated with ECMO have the same 1-year conditional survival as patients not having suffered EGF.